We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+3.16%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.43B
AUM Growth
+$53M
Cap. Flow
+$216M
Cap. Flow %
8.89%
Top 10 Hldgs %
47.1%
Holding
78
New
18
Increased
12
Reduced
15
Closed
20

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$82.2M
2
ALKS icon
Alkermes
ALKS
+$81.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$62.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$61.1M
5
GERN icon
Geron
GERN
+$55.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$85.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$68.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$56.9M
4
IMVT icon
Immunovant
IMVT
+$39.5M
5
ALBO
Albireo Pharma Inc
ALBO
+$36.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
1
Jazz Pharmaceuticals
JAZZ
$16.1B
$176M 7.21%
1,200,000
+326,447
+37% +$48.3M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$158M 6.5%
6,500,000
-1,378,119
-17% -$30.2M
TVTX icon
3
Travere Therapeutics
TVTX
$5.12B
$138M 5.68%
6,147,268
+1,565,268
+34% +$33.3M
IMVT icon
4
Immunovant
IMVT
$7.8B
$115M 4.73%
7,432,717
-2,277,283
-23% -$39.5M
INSM icon
5
Insmed
INSM
$22.6B
$111M 4.55%
6,500,000
+2,235,708
+52% +$43.4M
IONS icon
6
Ionis Pharmaceuticals
IONS
$9.04B
$101M 4.16%
2,834,069
+1,628,296
+135% +$61.1M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$92.1M 3.78%
+1,700,000
New +$82.2M
PLRX icon
8
Pliant Therapeutics
PLRX
$65.6M
$91M 3.74%
3,422,057
+1,689,111
+97% +$48.1M
ALKS icon
9
Alkermes
ALKS
$8.08B
$84.6M 3.47%
+3,000,000
New +$81.7M
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$79.8M 3.28%
3,100,000
-9,886
-0.3% -$289K
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$69.5M 2.85%
3,000,000
– –
RETA
12
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$66.3M 2.72%
+729,000
New +$42.8M
VRNA
13
DELISTED
Verona Pharma
VRNA
$64M 2.63%
3,187,415
– –
GPCR icon
14
Structure Therapeutics
GPCR
$3.38B
$63M 2.59%
+2,646,782
New +$62.2M
DVAX
15
DELISTED
Dynavax Technologies
DVAX
$62.3M 2.56%
6,350,000
+4,022,049
+173% +$42.9M
BCYC
16
Bicycle Therapeutics
BCYC
$269M
$60M 2.46%
2,819,045
– –
GERN icon
17
Geron
GERN
$911M
$58.3M 2.39%
26,867,479
+19,452,786
+262% +$55.2M
BIIB icon
18
Biogen
BIIB
$31.1B
$55.6M 2.28%
200,000
-100,000
-33% -$27.7M
DICE
19
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$45.8M 1.88%
1,600,000
-134,143
-8% -$3.97M
AGEN
20
Agenus
AGEN
$280M
$45.6M 1.87%
1,528,500
+152,850
+11% +$6.46M
SGEN
21
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$44.1M 1.81%
+217,800
New +$34.9M
PACB icon
22
Pacific Biosciences
PACB
$432M
$40.6M 1.67%
+3,504,390
New +$34.8M
FDMT icon
23
4D Molecular Therapeutics
FDMT
$496M
$39.2M 1.61%
2,278,107
-378,794
-14% -$7.37M
BEAM icon
24
Beam Therapeutics
BEAM
$2.68B
$38.3M 1.57%
1,250,000
+83,527
+7% +$3.3M
EXEL icon
25
Exelixis
EXEL
$14B
$37.5M 1.54%
+1,931,874
New +$33.7M
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Deep Track Capital held 78 positions worth $2.43B, up 2.2% from $2.38B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deep Track Capital deployed $216M of net new capital in Q1 2023, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $39.5M trimmed.

  • Deep Track Capital's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 1,700,000 shares worth $92.1M.
  • Deep Track Capital added most to Ionis Pharmaceuticals in Q1 2023, an estimated $61.1M increase.
  • Deep Track Capital's biggest Q1 2023 reduction was Immunovant, cutting an estimated $39.5M.
  • Deep Track Capital fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $85.5M.
  • Deep Track Capital's ten largest holdings make up 47% of its $2.43B portfolio in Q1 2023.
  • Deep Track Capital opened 18 new positions and closed 20 in Q1 2023.
  • Deep Track Capital's portfolio value rose 2.2% quarter-over-quarter to $2.43B.

Based on Deep Track Capital's 13F filing for Q1 2023, filed 15 May 2023.